{"id":29179,"date":"2025-03-14T01:17:54","date_gmt":"2025-03-13T17:17:54","guid":{"rendered":"https:\/\/flcube.com\/?p=29179"},"modified":"2025-03-14T01:17:56","modified_gmt":"2025-03-13T17:17:56","slug":"harbour-biomed-launches-elance-therapeutics-to-tackle-obesity-treatment-challenges","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29179","title":{"rendered":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges"},"content":{"rendered":"\n

China-based Harbour BioMed (HKG: 2142<\/a>) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed’s commitment to expanding its presence in the global obesity treatment market.<\/p>\n\n\n\n

Technological Edge and Pipeline<\/strong>
\u00c9lanc\u00e9 Therapeutics will leverage Harbour BioMed’s proprietary HCAb-based bispecific antibody (BsAb) technology to advance the development of next-generation obesity treatments. The subsidiary boasts a product pipeline comprising multiple pre-clinical BsAb programs that utilize innovative mechanisms such as targeted hormone regulation and enhanced metabolic regulation to achieve therapeutic effects.<\/p>\n\n\n\n

AI Platform Integration<\/strong>
\u00c9lanc\u00e9 will refine and expand the Hu-mAtrIx AI platform of Nona Biosciences, a wholly-owned subsidiary of Harbour BioMed, to support BsAb discovery. AI applications will guide antibody sequence discovery, enrichment, optimization, bispecific geometry design, and assessments of developability, immunogenicity, and pharmacokinetics (PK), as well as patient biomarker studies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused…<\/p>\n","protected":false},"author":1,"featured_media":29181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[3850,190,916,86],"class_list":["post-29179","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-elance-therapeutics","tag-harbour-biomed","tag-hkg-2142","tag-obesity"],"yoast_head":"\nHarbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29179\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges\" \/>\n<meta property=\"og:description\" content=\"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29179\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-13T17:17:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-13T17:17:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges\",\"datePublished\":\"2025-03-13T17:17:54+00:00\",\"dateModified\":\"2025-03-13T17:17:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1309-png.avif\",\"keywords\":[\"\u00c9lanc\u00e9 Therapeutics\",\"Harbour BioMed\",\"HKG: 2142\",\"Obesity\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29179#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29179\",\"name\":\"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1309-png.avif\",\"datePublished\":\"2025-03-13T17:17:54+00:00\",\"dateModified\":\"2025-03-13T17:17:56+00:00\",\"description\":\"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29179\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1309-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1309-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Harbour BioMed \u00c9lanc\u00e9 Therapeutics Obesity Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29179#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges - Insight, China's Pharmaceutical Industry","description":"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29179","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges","og_description":"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.","og_url":"https:\/\/flcube.com\/?p=29179","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-13T17:17:54+00:00","article_modified_time":"2025-03-13T17:17:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29179#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29179"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges","datePublished":"2025-03-13T17:17:54+00:00","dateModified":"2025-03-13T17:17:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29179"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29179#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","keywords":["\u00c9lanc\u00e9 Therapeutics","Harbour BioMed","HKG: 2142","Obesity"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29179#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29179","url":"https:\/\/flcube.com\/?p=29179","name":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29179#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29179#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","datePublished":"2025-03-13T17:17:54+00:00","dateModified":"2025-03-13T17:17:56+00:00","description":"China-based Harbour BioMed (HKG: 2142) announced the establishment of \u00c9lanc\u00e9 Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed's commitment to expanding its presence in the global obesity treatment market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29179#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29179"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29179#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","width":1080,"height":608,"caption":"Harbour BioMed \u00c9lanc\u00e9 Therapeutics Obesity Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29179#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Launches \u00c9lanc\u00e9 Therapeutics to Tackle Obesity Treatment Challenges"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1309-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29179"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29179\/revisions"}],"predecessor-version":[{"id":29182,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29179\/revisions\/29182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}